Campath BLA For Chronic Lymphocytic Leukemia Has June User Fee Goal
This article was originally published in Pharmaceutical Approvals Monthly
Millennium Pharmaceuticals and Ilex Oncology are hoping to launch their monoclonal antibody Campath (alemtuzumab) before the end of 2000 for treatment of B-cell chronic lymphocytic leukemia (CLL) in patients refractory to first- and second-line therapy.
You may also be interested in...
Evidence within compendia to support the off-label use of targeted cancer therapies varies widely and is rapidly evolving, making it difficult to draw solid conclusions regarding safety and efficacy, according to a draft technology assessment report released for comment by the Agency for Healthcare Research and Quality
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011